Merck KGaA Announces Extension of FDA Priority Review Period for Cladribine Tablets for the Treatment of Relapsing Forms of MS
FDA extends Priority Review period of Cladribine Tablets by three months
The FDA granted Priority Review status for Cladribine Tablets in July of 2010, reducing the standard 10-month review period to six months, which was set to end on November 28, 2010. The FDA extended the review period to provide additional time for a full review of additional information provided under the new drug application (NDA).
“Merck Serono continues to work closely with the FDA during the review process of the Cladribine Tablets new drug application,” said Bernhard Kirschbaum, Merck Serono’s Head of Global Research and Development. “We will continue working towards our goal of providing an oral disease-modifying drug for the treatment of relapsing multiple sclerosis.”
Organizations
Other news from the department research and development
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.